Pharvaris (NASDAQ:PHVS) Trading Down 5.7% – Here’s Why

Posted by Hayley Millar on Mar 5th, 2025

Pharvaris (NASDAQ:PHVS – Get Free Report)’s share price was down 5.7% during trading on Wednesday . The stock traded as low as $14.98 and last traded at $14.57. Approximately 93,257 shares were traded during mid-day trading, an increase of 100% from the average daily volume of 46,548 shares. The stock had previously closed at $15.45.

Wall Street Analysts Forecast Growth

Separately, JMP Securities raised their price target on Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Friday, January 31st.

View Our Latest Stock Analysis on PHVS

Pharvaris Price Performance

The firm has a market capitalization of $783.83 million, a price-to-earnings ratio of -5.35 and a beta of -3.08. The company’s 50-day moving average is $17.65 and its 200-day moving average is $19.27.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors have recently added to or reduced their stakes in the company. Public Employees Retirement System of Ohio purchased a new stake in shares of Pharvaris in the third quarter valued at $57,000. JPMorgan Chase & Co. increased its holdings in shares of Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock worth $59,000 after purchasing an additional 2,847 shares during the period. Cubist Systematic Strategies LLC acquired a new stake in shares of Pharvaris during the 4th quarter valued at about $64,000. Barclays PLC acquired a new stake in shares of Pharvaris during the 3rd quarter worth about $106,000. Finally, KLP Kapitalforvaltning AS acquired a new position in Pharvaris during the 4th quarter worth about $111,000.

About Pharvaris

(Get Free Report)

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.